JIP
RXRX icon

Jaffetilchin Investment Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,401
Closed -$154K – 460
2025
Q2 		$154K Buy
+30,401
New +$149K 0.01% 422
2025
Q1 		– Sell
-21,754
Closed -$147K – 437
2024
Q4 		$147K Buy
+21,754
New +$146K 0.01% 378

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jaffetilchin Investment Partners's RXRX Position: Q3 2025 in Review

Jaffetilchin Investment Partners sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 30,401 shares — an estimated $154K sold.

Jaffetilchin Investment Partners first reported a position in RXRX in Q4 2024 and held it in 2 quarters. The position peaked at $154K in Q2 2025. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Jaffetilchin Investment Partners reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 30,401 Recursion Pharmaceuticals shares in Q3 2025, an estimated $154K.
  • Jaffetilchin Investment Partners first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Jaffetilchin Investment Partners's Recursion Pharmaceuticals position peaked at $154K in Q2 2025.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Jaffetilchin Investment Partners's 13F filing for Q3 2025, filed 13 Nov 2025.